|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
EP0039369B1
(en)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
IL104068A
(en)
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
|
|
US5683676A
(en)
*
|
1991-12-12 |
1997-11-04 |
Glaxo Group Limited |
Canister containing aerosol formulations containing P134a and particulate medicaments
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
CA2421976C
(en)
|
1991-12-12 |
2004-04-20 |
Glaxo Group Limited |
Medicaments
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
WO1993025198A1
(en)
*
|
1992-06-12 |
1993-12-23 |
Teijin Limited |
Ultrafine powder for inhalation and production thereof
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
WO1994022427A1
(en)
*
|
1993-04-01 |
1994-10-13 |
Amgen Inc. |
Method for preparing drugs to treat dermal disorders
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
MX9700939A
(es)
|
1994-08-09 |
1997-04-30 |
Schering Corp |
PROCESO PARA PREPARAR CLATRATO DE FREON- beta DE DIPROPIONATO DE BECLOMETASONA.
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5872101A
(en)
*
|
1995-01-06 |
1999-02-16 |
Sibia Neurosciences, Inc. |
Methods of treating neurodegenerative disorders using protease inhibitors
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
*
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
DE69736981D1
(de)
*
|
1996-05-01 |
2007-01-04 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
US6599927B2
(en)
|
1996-10-11 |
2003-07-29 |
Astrazeneca Ab |
Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
|
|
US6458547B1
(en)
|
1996-12-12 |
2002-10-01 |
Prolume, Ltd. |
Apparatus and method for detecting and identifying infectious agents
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700135D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
TR200101905T2
(tr)
|
1997-04-28 |
2002-06-21 |
Texas Biotechnology Corporation |
Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
AU2868099A
(en)
|
1998-02-13 |
1999-08-30 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
|
EP1925320A3
(en)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
|
|
EP1100520B1
(en)
*
|
1998-07-21 |
2004-09-22 |
Cytovia, Inc. |
Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
WO2001036351A2
(en)
|
1999-11-19 |
2001-05-25 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
ATE286051T1
(de)
|
1999-12-31 |
2005-01-15 |
Encysive Pharmaceuticals Inc |
Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
WO2003032916A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
AU2002367060A1
(en)
*
|
2001-12-21 |
2003-07-30 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
EP1517684B1
(en)
|
2002-06-27 |
2009-07-22 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
WO2004005289A2
(en)
|
2002-07-02 |
2004-01-15 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
CA2506415A1
(en)
*
|
2002-11-19 |
2004-06-03 |
Achillion Pharmaceuticals, Inc. |
Substituted aryl thioureas and releated compounds; inhibitors of viral replication
|
|
AU2003293361A1
(en)
*
|
2002-12-18 |
2004-07-29 |
Glaxo Group Limited |
Drug delivery system with vented mouthpiece
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
ES2335005T5
(es)
|
2003-03-05 |
2013-04-17 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
|
KR20060023529A
(ko)
*
|
2003-05-14 |
2006-03-14 |
토레이파인스 테라퓨틱스, 인코포레이티드 |
화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도
|
|
PT1635824E
(pt)
*
|
2003-06-03 |
2009-11-24 |
Novartis Ag |
Inibidores de p-38 à base de heterociclos de 5 membros
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
WO2005090282A1
(en)
*
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
CN101198598A
(zh)
|
2004-05-20 |
2008-06-11 |
弗尔德里克斯制药股份有限公司 |
2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
|
|
US20060135773A1
(en)
*
|
2004-06-17 |
2006-06-22 |
Semple Joseph E |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
US20100190688A1
(en)
|
2004-07-12 |
2010-07-29 |
Bin Chao |
Tetrapeptide analogs
|
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
AU2005287137B2
(en)
|
2004-09-17 |
2012-03-22 |
Foldrx Pharmaceuticals, Inc. |
Compounds, compositions and methods of inhibiting a-synuclein toxicity
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
JP2008524331A
(ja)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
|
CN101189249B
(zh)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
膦酰基-戊-2-烯-1-基核苷和类似物
|
|
US20060251619A1
(en)
*
|
2005-05-04 |
2006-11-09 |
Gilles Borrelly |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
CN101137655A
(zh)
*
|
2005-06-17 |
2008-03-05 |
配体药物公司 |
雄激素受体调节剂化合物和方法
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
WO2007047995A2
(en)
|
2005-10-21 |
2007-04-26 |
Catalyst Biosciences, Inc. |
Modified proteases that inhibit complement activation
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
PL2383271T3
(pl)
*
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
|
US20080038224A1
(en)
*
|
2006-03-28 |
2008-02-14 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
US20100273776A1
(en)
*
|
2006-03-29 |
2010-10-28 |
FOLDRx PHARMACEUTICALS, INC |
Inhibition of alpha-synuclein toxicity
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
TW200804416A
(en)
|
2006-06-19 |
2008-01-16 |
Nautilus Technology Llc |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
PL2066662T3
(pl)
|
2006-09-21 |
2013-05-31 |
Kyorin Seiyaku Kk |
Inhibitory hydrolaz serynowych
|
|
EP2079696A2
(en)
|
2006-10-09 |
2009-07-22 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP2223925A1
(en)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
CA2667961A1
(en)
|
2006-10-31 |
2008-05-08 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
JP2010510794A
(ja)
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
|
WO2009070164A1
(en)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Vigor enhancement via administration of pyrimidine derivatives
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
MX2009006812A
(es)
*
|
2006-12-22 |
2009-07-02 |
Encysive Pharmaceuticals Inc |
Moduladores del receptor c3a y metodos de uso de los mismos.
|
|
KR20150041804A
(ko)
|
2007-02-11 |
2015-04-17 |
맵 파마슈티컬스, 인코포레이티드 |
부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
|
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
|
AU2008299903B2
(en)
*
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
|
KR20140097440A
(ko)
|
2007-09-25 |
2014-08-06 |
다케다 야쿠힌 고교 가부시키가이샤 |
폴로형 키나아제 억제제
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
NZ585528A
(en)
|
2007-11-21 |
2012-08-31 |
Pharmaxis Ltd |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
WO2009082437A2
(en)
|
2007-12-21 |
2009-07-02 |
Ligand Pharmaceuticals Incorporated |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
CA2721229C
(en)
|
2008-04-14 |
2022-08-23 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
WO2010008847A2
(en)
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
|
EA022752B1
(ru)
|
2008-12-09 |
2016-02-29 |
Галозим, Инк. |
Длинные растворимые полипептиды рн20 и их использование
|
|
EP2373693A4
(en)
|
2009-01-06 |
2012-04-25 |
Curelon Llc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
|
|
GB2480772B
(en)
|
2009-01-06 |
2013-10-16 |
Curelon Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
|
|
EP2403523A1
(en)
*
|
2009-03-06 |
2012-01-11 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
|
WO2010111626A2
(en)
|
2009-03-27 |
2010-09-30 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459561A1
(en)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
EP2515654A4
(en)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
NEW ERGOLINANALOGA
|
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
|
CN102834393B
(zh)
|
2010-02-03 |
2015-07-22 |
武田药品工业株式会社 |
细胞凋亡信号调节激酶1抑制剂
|
|
EP2585455B1
(en)
|
2010-06-24 |
2019-08-07 |
The Regents of the University of California |
Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
|
|
WO2012145651A2
(en)
|
2011-04-21 |
2012-10-26 |
Curemark, Llc |
Compounds for the treatment of neuropsychiatric disorders
|
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
DK3130347T3
(da)
|
2011-12-30 |
2019-10-14 |
Halozyme Inc |
PH20-polypeptidvarianter, formuleringer og anvendelser deraf
|
|
WO2013134047A2
(en)
|
2012-03-07 |
2013-09-12 |
The Mclean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
|
CN107266332B
(zh)
|
2012-05-02 |
2020-07-24 |
勃林格殷格翰国际有限公司 |
Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP3406598B1
(en)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
|
US11058659B2
(en)
|
2013-02-22 |
2021-07-13 |
University Of Southern California |
Methods and compositions for the treatment of ophalmic diseases and disorders
|
|
US9938263B2
(en)
|
2013-03-12 |
2018-04-10 |
The General Hospital Corporation |
Gamma-secretase modulators
|
|
CA2911376C
(en)
|
2013-03-15 |
2021-03-30 |
University Of Southern California |
Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases
|
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
MX2016014731A
(es)
|
2014-05-12 |
2017-05-04 |
Conatus Pharmaceuticals Inc |
Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
|
|
EA201692458A1
(ru)
|
2014-05-28 |
2017-06-30 |
Агенус Инк. |
Анти-gitr антитела и способы их применения
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
DK3207130T3
(da)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
|
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
JP6672296B2
(ja)
|
2014-10-31 |
2020-03-25 |
ザ ジェネラル ホスピタル コーポレイション |
強力なγ−セクレターゼモジュレータ
|
|
SG11201704752WA
(en)
|
2014-12-11 |
2017-07-28 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
ES2862701T3
(es)
|
2014-12-22 |
2021-10-07 |
Univ Rockefeller |
Anticuerpos agonistas anti-MERTK y usos de los mismos
|
|
BR112017015487A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
|
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
イソエルゴリン化合物およびその使用
|
|
PT3265123T
(pt)
|
2015-03-03 |
2023-02-01 |
Kymab Ltd |
Anticorpos, usos e métodos
|
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
|
BR112017025564B8
(pt)
|
2015-05-29 |
2022-01-04 |
Agenus Inc |
Anticorpos anti-ctla-4 e métodos de uso dos mesmos
|
|
ES2901506T3
(es)
|
2015-08-17 |
2022-03-22 |
Kura Oncology Inc |
Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
|
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
US20190022043A1
(en)
|
2015-12-31 |
2019-01-24 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
|
SG10202003099XA
(en)
|
2016-01-08 |
2020-05-28 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
US10407437B2
(en)
|
2016-03-08 |
2019-09-10 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
ES2939373T3
(es)
|
2016-05-13 |
2023-04-21 |
Pasteur Institut |
Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
TWI843168B
(zh)
|
2016-10-11 |
2024-05-21 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
PT3534885T
(pt)
|
2016-11-03 |
2021-04-13 |
Kura Oncology Inc |
Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
MA50948A
(fr)
|
2016-12-07 |
2020-10-14 |
Agenus Inc |
Anticorps et procédés d'utilisation de ceux-ci
|
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP4119142A1
(en)
|
2017-02-21 |
2023-01-18 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
|
HRP20230941T1
(hr)
|
2017-05-01 |
2023-11-24 |
Agenus Inc. |
Anti-tigit antitijela i postupci njihove primjene
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
KR102675270B1
(ko)
|
2017-06-22 |
2024-06-17 |
버텍스 파마슈티칼스 인코포레이티드 |
변형된 막 유형 세린 프로테아제 １(ｍｔｓｐ－１) 폴리펩티드 및 사용 방법
|
|
CN110996983A
(zh)
|
2017-06-26 |
2020-04-10 |
巴斯德研究所 |
清除hiv储库并降低病毒载量的治疗
|
|
EP3645040A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
|
|
US11746149B2
(en)
|
2017-06-27 |
2023-09-05 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
|
|
WO2019003159A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
|
|
KR20230130162A
(ko)
|
2017-06-27 |
2023-09-11 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
WO2019014398A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
|
JP7051150B2
(ja)
|
2017-10-02 |
2022-04-11 |
ニューラクル サイエンス カンパニー リミテッド |
気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途
|
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CA3097999A1
(en)
|
2018-04-24 |
2019-10-31 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
|
JP7530638B2
(ja)
|
2018-05-10 |
2024-08-08 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
|
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
|
JP2022506463A
(ja)
|
2018-11-01 |
2022-01-17 |
クラ オンコロジー， インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤でがんを治療する方法
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
EP3897638A1
(en)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
AU2019413431A1
(en)
|
2018-12-28 |
2021-07-08 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
JP2022522344A
(ja)
|
2019-02-26 |
2022-04-18 |
インスピアーナ， インコーポレイテッド |
高親和性抗ｍｅｒｔｋ抗体およびその使用
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
SG11202108459QA
(en)
|
2019-02-27 |
2021-09-29 |
Actym Therapeutics Inc |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
AU2020231396A1
(en)
|
2019-03-07 |
2021-10-21 |
Nobo Medicine Inc. |
Caspase inhibitors and methods of use thereof
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR20210144778A
(ko)
|
2019-03-29 |
2021-11-30 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
US20220249707A1
(en)
|
2019-05-20 |
2022-08-11 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
BR112022003740A2
(pt)
|
2019-08-30 |
2022-05-31 |
Agenus Inc |
Anticorpos anti-cd96 e métodos de uso dos mesmos
|
|
AU2020348685A1
(en)
|
2019-09-16 |
2022-04-14 |
Dice Alpha, Inc. |
IL-17A modulators and uses thereof
|
|
AU2020382614A1
(en)
|
2019-11-12 |
2022-06-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
AU2021207586A1
(en)
|
2020-01-13 |
2022-07-21 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
|
|
US20230210952A1
(en)
|
2020-02-05 |
2023-07-06 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
CN116615236A
(zh)
|
2020-11-05 |
2023-08-18 |
新免疫技术有限公司 |
用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
|
CR20230472A
(es)
|
2021-03-10 |
2024-03-21 |
Dice Molecules Sv Inc |
Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
|
WO2023069770A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
IL312506A
(en)
|
2021-11-08 |
2024-07-01 |
Progentos Therapeutics Inc |
Platelet-based alpha inhibitors and their uses
|
|
KR20240130705A
(ko)
|
2021-12-30 |
2024-08-29 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
|
|
EP4433040A2
(en)
|
2022-01-03 |
2024-09-25 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
|
WO2023198757A1
(en)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
|
WO2024086852A1
(en)
|
2022-10-21 |
2024-04-25 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|